Cargando…

8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland

The 8th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The new agenda format for 2012 included three parallel tracks on: (1) naked antibodies; (2) antibody drug conjugates (ADCs); and (3) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Alain, Carter, Paul J., Gerber, Hans-Peter, Lugovskoy, Alexey A., Wurch, Thierry, Junutula, Jagath R., Kontermann, Roland E, Mabry, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169028/
https://www.ncbi.nlm.nih.gov/pubmed/23493119
http://dx.doi.org/10.4161/mabs.24105
_version_ 1782335655688273920
author Beck, Alain
Carter, Paul J.
Gerber, Hans-Peter
Lugovskoy, Alexey A.
Wurch, Thierry
Junutula, Jagath R.
Kontermann, Roland E
Mabry, Robert
author_facet Beck, Alain
Carter, Paul J.
Gerber, Hans-Peter
Lugovskoy, Alexey A.
Wurch, Thierry
Junutula, Jagath R.
Kontermann, Roland E
Mabry, Robert
author_sort Beck, Alain
collection PubMed
description The 8th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The new agenda format for 2012 included three parallel tracks on: (1) naked antibodies; (2) antibody drug conjugates (ADCs); and (3) bispecific antibodies and alternative scaffolds. The meeting started and closed with three plenary lectures to give common background and to share the final panel discussion and conclusions. The two day event included case studies and networking for nearly 250 delegates who learned of the latest advances and trends in the global development of antibody-based therapeutics. The monoclonal antibody track was focused on understanding the structure-function relationships, optimization of antibody design and developability, and processes that allow better therapeutic candidates to move through the clinic. Discussions on novel target identification and validation were also included. The ADC track was dedicated to evaluation of the ongoing success of the established ADC formats alongside the rise of the next generation drug-conjugates. The bispecific and alternative scaffold track was focused on taking stock of the multitude of bispecific formats being investigated and gaining insight into recent innovations and advancements. Mechanistic understanding, progression into the clinic and the exploration of multispecifics, redirected T cell killing and alternative scaffolds were extensively discussed. In total, nearly 50 speakers provided updates of programs related to antibody research and development on-going in the academic, government and commercial sectors.
format Online
Article
Text
id pubmed-4169028
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41690282014-09-24 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland Beck, Alain Carter, Paul J. Gerber, Hans-Peter Lugovskoy, Alexey A. Wurch, Thierry Junutula, Jagath R. Kontermann, Roland E Mabry, Robert MAbs Meeting Report The 8th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The new agenda format for 2012 included three parallel tracks on: (1) naked antibodies; (2) antibody drug conjugates (ADCs); and (3) bispecific antibodies and alternative scaffolds. The meeting started and closed with three plenary lectures to give common background and to share the final panel discussion and conclusions. The two day event included case studies and networking for nearly 250 delegates who learned of the latest advances and trends in the global development of antibody-based therapeutics. The monoclonal antibody track was focused on understanding the structure-function relationships, optimization of antibody design and developability, and processes that allow better therapeutic candidates to move through the clinic. Discussions on novel target identification and validation were also included. The ADC track was dedicated to evaluation of the ongoing success of the established ADC formats alongside the rise of the next generation drug-conjugates. The bispecific and alternative scaffold track was focused on taking stock of the multitude of bispecific formats being investigated and gaining insight into recent innovations and advancements. Mechanistic understanding, progression into the clinic and the exploration of multispecifics, redirected T cell killing and alternative scaffolds were extensively discussed. In total, nearly 50 speakers provided updates of programs related to antibody research and development on-going in the academic, government and commercial sectors. Landes Bioscience 2013-05-01 2013-03-14 /pmc/articles/PMC4169028/ /pubmed/23493119 http://dx.doi.org/10.4161/mabs.24105 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Meeting Report
Beck, Alain
Carter, Paul J.
Gerber, Hans-Peter
Lugovskoy, Alexey A.
Wurch, Thierry
Junutula, Jagath R.
Kontermann, Roland E
Mabry, Robert
8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title_full 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title_fullStr 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title_full_unstemmed 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title_short 8(th) Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
title_sort 8(th) annual european antibody congress 2012: november 27–28, 2012, geneva, switzerland
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169028/
https://www.ncbi.nlm.nih.gov/pubmed/23493119
http://dx.doi.org/10.4161/mabs.24105
work_keys_str_mv AT beckalain 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT carterpaulj 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT gerberhanspeter 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT lugovskoyalexeya 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT wurchthierry 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT junutulajagathr 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT kontermannrolande 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland
AT mabryrobert 8thannualeuropeanantibodycongress2012november27282012genevaswitzerland